中国实用医药
中國實用醫藥
중국실용의약
CHINA PRACTICAL MEDICAL
2015年
5期
10-12
,共3页
“H型”高血压%颈动脉粥样硬化%同型半胱氨酸%非洛地平%卡托普利%叶酸%B族维生素
“H型”高血壓%頸動脈粥樣硬化%同型半胱氨痠%非洛地平%卡託普利%葉痠%B族維生素
“H형”고혈압%경동맥죽양경화%동형반광안산%비락지평%잡탁보리%협산%B족유생소
H-type hypertension%Carotid artery atherosclerosis%Homocysteine%Felodipine%Captopril%Folic acid%Vitamins B
目的：通过观察非洛地平、卡托普利、叶酸及B族维生素联合干预“H型”高血压患者血压、颈动脉内膜中层厚度(CAIMT)及血清同型半胱氨酸(HCY)水平变化,探讨药物联合干预“H型”高血压的临床疗效。方法86例“H型”高血压患者实施非洛地平、卡托普利、叶酸及B族维生素联合干预8周,对比分析干预前后血压、CAIMT及血清HCY水平变化。结果患者组干预前收缩压(SBP)、舒张压(DBP)、血清HCY水平及CAIMT(168.9±10.4)mm Hg,(92.5±11.3)mm Hg,(24.7±5.3)μmol/L,(0.98±0.19) mm均显著高于对照组(123.5±6.6)mm Hg,(71.8±7.9)mm Hg,(9.8±2.7)μmol/L,(0.57±0.14)mm,差异具有统计学意义(P<0.01),干预后SBP、DBP、血清HCY水平及CAIMT(130.2±8.9)mm Hg,(78.7±8.6)mm Hg,(10.9±4.2)μmol/L,(0.76±0.13)mm均显著低于干预前,差异具有统计学意义(P<0.01)。药物联合干预“H型”高血压患者的总有效率为95.3%(82/86)。结论非洛地平、卡托普利、叶酸及B族维生素联合干预“H型”高血压患者,可显著改善血压、颈动脉粥样硬化及血液HCY水平,临床疗效显著。
目的：通過觀察非洛地平、卡託普利、葉痠及B族維生素聯閤榦預“H型”高血壓患者血壓、頸動脈內膜中層厚度(CAIMT)及血清同型半胱氨痠(HCY)水平變化,探討藥物聯閤榦預“H型”高血壓的臨床療效。方法86例“H型”高血壓患者實施非洛地平、卡託普利、葉痠及B族維生素聯閤榦預8週,對比分析榦預前後血壓、CAIMT及血清HCY水平變化。結果患者組榦預前收縮壓(SBP)、舒張壓(DBP)、血清HCY水平及CAIMT(168.9±10.4)mm Hg,(92.5±11.3)mm Hg,(24.7±5.3)μmol/L,(0.98±0.19) mm均顯著高于對照組(123.5±6.6)mm Hg,(71.8±7.9)mm Hg,(9.8±2.7)μmol/L,(0.57±0.14)mm,差異具有統計學意義(P<0.01),榦預後SBP、DBP、血清HCY水平及CAIMT(130.2±8.9)mm Hg,(78.7±8.6)mm Hg,(10.9±4.2)μmol/L,(0.76±0.13)mm均顯著低于榦預前,差異具有統計學意義(P<0.01)。藥物聯閤榦預“H型”高血壓患者的總有效率為95.3%(82/86)。結論非洛地平、卡託普利、葉痠及B族維生素聯閤榦預“H型”高血壓患者,可顯著改善血壓、頸動脈粥樣硬化及血液HCY水平,臨床療效顯著。
목적：통과관찰비락지평、잡탁보리、협산급B족유생소연합간예“H형”고혈압환자혈압、경동맥내막중층후도(CAIMT)급혈청동형반광안산(HCY)수평변화,탐토약물연합간예“H형”고혈압적림상료효。방법86례“H형”고혈압환자실시비락지평、잡탁보리、협산급B족유생소연합간예8주,대비분석간예전후혈압、CAIMT급혈청HCY수평변화。결과환자조간예전수축압(SBP)、서장압(DBP)、혈청HCY수평급CAIMT(168.9±10.4)mm Hg,(92.5±11.3)mm Hg,(24.7±5.3)μmol/L,(0.98±0.19) mm균현저고우대조조(123.5±6.6)mm Hg,(71.8±7.9)mm Hg,(9.8±2.7)μmol/L,(0.57±0.14)mm,차이구유통계학의의(P<0.01),간예후SBP、DBP、혈청HCY수평급CAIMT(130.2±8.9)mm Hg,(78.7±8.6)mm Hg,(10.9±4.2)μmol/L,(0.76±0.13)mm균현저저우간예전,차이구유통계학의의(P<0.01)。약물연합간예“H형”고혈압환자적총유효솔위95.3%(82/86)。결론비락지평、잡탁보리、협산급B족유생소연합간예“H형”고혈압환자,가현저개선혈압、경동맥죽양경화급혈액HCY수평,림상료효현저。
Objective To explore the clinical effect of joint drug intervention of H-type hypertension through observation of level changes of blood pressure, carotid intima-media thickness (CAIMT) and serum homocysteine (HCY) in H-type hypertension patients intervened by felodipine, captopril, folic acid, and vitamins B. Methods A total of 86 H-type hypertension patients received joint intervention by felodipine, captopril, folic acid, and vitamins B for 8 weeks. The level changes of blood pressure, CAIMT, and serum HCY were compared before and after intervention. Results The patient group had obviously higher levels of systolic blood pressure (SBP), diastolic blood pressure (DBP), serum HCY and CAIMT before intervetion, as (168.9±10.4) mmHg, (92.5±11.3) mmHg, (24.7±5.3)μmol/L, and (0.98±0.19) mm, than the control group, as (123.5±6.6) mmHg, (71.8±7.9) mmHg, (9.8±2.7)μmol/L, (0.57±0.14) mm. The difference had statistical significance (P<0.01). After intervention, the levels of SBP, DBP, serum HCY, and CAIMT, as (130.2±8.9) mmHg, (78.7±8.6) mmHg, (10.9±4.2)μmol/L, (0.76±0.13) mm, were lower than those before intervention. The difference had statistical significance (P<0.01). The total effective rate of joint drug intervention of H-type hypertension was 95.3%(82/86).Conclusion Joint intervention by felodipine, captopril, folic acid, and vitamins B for H-type hypertension can remarkably improve blood pressure, carotid artery atherosclerosis, and serum HCY level with significant clinical effect.
